他莫昔芬序贯来曲唑与来曲唑单药治疗乳腺癌的临床对比

Clinical Comparison of Sequential Tamoxifen and Single-drug of Letrozole in Treatment of Breast Cancer

目的研究探讨他莫昔芬序贯来曲唑与来曲唑单药治疗乳腺癌的临床效果比较。方法拟定此研究于2010年1月—2012年12月在该院进行,以规定研究时段内收治的50例晚期绝经后乳腺癌患者为研究对象,随机均分两组各25例,以来曲唑单药治疗为对照组,以他莫昔芬序贯来曲唑治疗为观察组,分析他莫昔芬序贯来曲唑治疗的价值所在,并对比两组的复发情况、生存率、不良反应。结果观察组患者1、3、5年的生存率及1、3年的复发率与对照组差异无统计学意义(P>0.05)而观察组5年复发例数明显较对照组少(χ~2=3.920,P=0.025)观察组不良反应的发生率为8.0%,对照组不良反应的发生率为28.0%,(χ~2=18.312,P<0.05)。结论他莫昔芬序贯来曲唑治疗乳腺癌患者,效果显著,可以减少不良反应的出现,安全性较高,还可以提高患者的生存率,减少复发,值得去推广和应用。

Objective To research and study the comparison of sequential tamoxifen and single drug of letrozole in treatment of breast cancer. Methods 50 cases of patients with advanced breast cancer after the menopause admitted and treated in our hospital from January 2010 to December 2012 were selected and randomly divided into two groups with 25 cases in each, the control group used the single drug of letrozole, while the observation group were treated with sequential tamoxifen, and the recurrence condition, survival rate and adverse reactions were compared between the two groups. Results The differences in the 1-year, 3-year and 5-year survival rates and 1-year recurrence rate and 3-year recurrence rate between the two groups were not statistically significant(P>0.05), and the 5-year recurrence cases in the observation group were obviously lower than those in the control group(χ^2=3.920, P=0.025), and the incidence rate of adverse reactions in the observation group and in the control group was respectively 8.0% and 28.0%,(χ^2=18.312, P<0.05). Conclusion The effect of sequential tamoxifen in treatment of breast cancer is obvious, which can reduce the occurrence of adverse reactions, with high safety, but also improve the survival rate of patients and reduce the recurrence, and it is worth promotion and application.